The financing will support Phase IIb proof-of-concept work for recurrent major depressive disorder and Delix’s broader neuroplastogen pipeline.
Discover more from Coin Gazette
Subscribe to get the latest posts sent to your email.
The financing will support Phase IIb proof-of-concept work for recurrent major depressive disorder and Delix’s broader neuroplastogen pipeline.
Subscribe to get the latest posts sent to your email.